Inflammatory Bowel Disease Centre and Department of Surgery, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan.
Colorectal Dis. 2013 Dec;15(12):1471-80. doi: 10.1111/codi.12326.
To review the optimal strategy to prevent recurrence of Crohn's disease (CD) after surgery, with particular emphasis on the risk factors that predict postoperative recurrence, methods of monitoring for recurrence and medications used to prevent postoperative recurrence.
MEDLINE and the Cochrane Library were searched for clinical trials and meta-analyses that studied postoperative recurrence and prophylactic medications in CD.
The most significant factor that predicted postoperative recurrence was patient smoking status. Smokers had an increased risk of recurrence (odds ratio = 2.15; 95% confidence interval (CI) = 1.42-3.27). Similarly, perforating CD appeared to be associated with a higher recurrence rate compared with nonperforating CD (hazard ratio = 1.50; 95% CI = 1.16-1.93). The optimal monitoring strategy for postoperative recurrence has yet to be established. Nonetheless, ileocolonoscopy is considered to be the gold standard. Noninvasive imaging techniques including contrast ultrasonography and capsule endoscopy appear to be useful for postoperative monitoring. A number of meta-analyses found that mesalazine, nitroimidazole antibiotics and purine analogues (azathioprine/6-mercaptopurine) significantly reduced the risk of postoperative recurrence when compared with placebo. Additionally, recent randomized controlled trials have suggested that an early intervention with infliximab is likely to prevent recurrence after ileocolonic resection. Likewise, in prospective studies, biological therapy (infliximab/adalimumab) reduced clinical and endoscopic CD activity in patients with early endoscopic recurrence after surgery.
Although additional evidence is necessary, endoscopic monitoring and treatment step-up should be used to prevent postoperative recurrence of CD.
综述预防克罗恩病(CD)术后复发的最佳策略,重点关注预测术后复发的风险因素、监测复发的方法和预防术后复发的药物。
检索 MEDLINE 和 Cochrane 图书馆中关于 CD 术后复发和预防药物的临床试验和荟萃分析。
预测术后复发的最重要因素是患者吸烟状况。吸烟者复发风险增加(优势比=2.15;95%置信区间(CI)=1.42-3.27)。同样,与非穿孔性 CD 相比,穿孔性 CD 似乎与更高的复发率相关(风险比=1.50;95% CI=1.16-1.93)。尚未确定术后复发的最佳监测策略。尽管如此,回结肠镜检查仍被认为是金标准。非侵入性成像技术,包括对比超声检查和胶囊内镜检查,似乎对术后监测有用。一些荟萃分析发现,与安慰剂相比,美沙拉嗪、硝基咪唑抗生素和嘌呤类似物(硫唑嘌呤/6-巯基嘌呤)显著降低了术后复发的风险。此外,最近的随机对照试验表明,在回结肠切除术后早期使用英夫利昔单抗进行干预可能预防复发。同样,在前瞻性研究中,生物治疗(英夫利昔单抗/阿达木单抗)降低了术后早期内镜复发患者的临床和内镜 CD 活动度。
尽管需要更多的证据,但应进行内镜监测和治疗升级,以预防 CD 的术后复发。